CompletedPhase 2NCT03587766
Oral Fexinidazole Dosing Regimens for the Treatment of Adults With Chronic Indeterminate Chagas Disease
Studying American trypanosomiasis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Drugs for Neglected Diseases
- Principal Investigator
- Joaquim Gascón, MDCentro de Salud Internacional, Hospital Clínico de Barcelona ISGlobal - Barcelona Institute for Global Health
- Intervention
- Fexinidazole(drug)
- Enrollment
- 45 enrolled
- Eligibility
- 18-60 years · All sexes
- Timeline
- 2017 – 2019
Study locations (1)
- Hospital Clinic, Barcelona, Catalunia, Spain
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03587766 on ClinicalTrials.govOther trials for American trypanosomiasis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06632600A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.Novartis Pharmaceuticals
- ENROLLING BY INVITATIONNCT07033325University-Based Chagas Testing in Salta Province, ArgentinaMundo Sano Foundation
- RECRUITINGPHASE3NCT04897516Shorter Benznidazole Regimens Compared to the Standard Regimen for Chagas DiseaseLaboratorio Elea Phoenix S.A.
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04984265SBRT in Chagas Disease Ventricular TachycardiaUniversity of Sao Paulo General Hospital
- ACTIVE NOT RECRUITINGPHASE3NCT04024163Prospective Study of Benznidazole for Chagas' Disease Children With Chronic Indeterminate Chagas DiseaseInsud Pharma